Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046–81.
Dowling JJ, Weihl CC, Spencer MJ. Molecular and cellular basis of genetically inherited skeletal muscle disorders. Nat Rev Mol Cell Biol. 2021;22(11):713–32.
Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019;9(1):22.
Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.
Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022.
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–90.
Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovasc Res. 2018;114(8):1073–81.
Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis. 2011;218(2):451–6.
de Moraes MT, de Souza FH, de Barros TB, Shinjo SK. Analysis of metabolic syndrome in adult dermatomyositis with a focus on cardiovascular disease. Arthritis Care Res (Hoboken). 2013;65(5):793–9.
de Souza FH, Shinjo SK. The high prevalence of metabolic syndrome in polymyositis. Clin Exp Rheumatol. 2014;32(1):82–7.
Zhen C, Wang Y, Wang H, Wang X. The risk of ischemic stroke in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol. 2021;40(10):4101–8.
Tisseverasinghe A, Bernatsky S, Pineau CA. Arterial events in persons with dermatomyositis and polymyositis. J Rheumatol. 2009;36(9):1943–6.
Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLoS ONE. 2012;7(3):e33442.
Lai YT, Dai YS, Yen MF, et al. Dermatomyositis is associated with an increased risk of cardiovascular and cerebrovascular events: a Taiwanese population-based longitudinal follow-up study. Br J Dermatol. 2013;168(5):1054–9.
Rai SK, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study. Rheumatology (Oxford). 2016;55(3):461–9.
Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701.
Opinc AH, Makowski MA, Lukasik ZM, Makowska JS. Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies? Heart Fail Rev. 2021;26(1):111–25.
Bae SS, Oganesian B, Golub I, Charles-Schoeman C. Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: a retrospective study. Clin Cardiol. 2020;43(7):732–42.
Borges IBP, Shinjo SK. Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatol Int. 2019;39(2):311–6.
Shelly S, Mielke MM, Mandrekar J, et al. Epidemiology and natural history of inclusion body myositis: a 40-year population-based study. Neurology. 2021;96(21):e2653–61.
Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord. 2014;24(1):4–15.
Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153–62.
Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-induced myopathy: translational studies from preclinical to clinical evidence. Int J Mol Sci. 2021;22(4):2070.
Sun Z, Xu D, Zhao L, et al. A new therapeutic effect of fenofibrate in Duchenne muscular dystrophy: the promotion of myostatin degradation. Br J Pharmacol. 2022;179(6):1237–50.
Schoser B, Montagnese F, Bassez G, et al. Consensus-based care recommendations for adults with myotonic dystrophy type 2. Neurol Clin Pract. 2019;9(4):343–53.
Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf. 2014;13(9):1227–39.
Gras-Champel V, Batteux B, Masmoudi K, Liabeuf S. Statin-induced myasthenia: a disproportionality analysis of the WHO’s VigiBase pharmacovigilance database. Muscle Nerve. 2019;60(4):382–6.
Watanabe Y, Suzuki S, Nishimura H, et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore). 2015;94(4):e416.
Oh SJ, Dhall R, Young A, Morgan MB, Lu L, Claussen GC. Statins may aggravate myasthenia gravis. Muscle Nerve. 2008;38(3):1101–7.
Khalid R, Ibad A, Thompson PD. Statins and myasthenia gravis. Muscle Nerve. 2016;54(3):509.
Parmar B, Francis PJ, Ragge NK. Statins, fibrates, and ocular myasthenia. Lancet. 2002;360(9334):717.
Krenn M, Grisold A, Wohlfarth P, et al. Pathomechanisms and clinical implications of myasthenic syndromes exacerbated and induced by medical treatments. Front Mol Neurosci. 2020;13:156.
Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223–8.
Macias Saint-Gerons D, Castro JL. Amyotrophic lateral sclerosis associated with statins A disproportionality analysis of the WHO Program for International Drug Monitoring database (VigiBase). Eur J Clin Pharmacol. 2019;75(4):587–9.
Chang MC, Kwak SG, Park JS, Park D. Relationship between statins and the risk of amyotrophic lateral sclerosis: a PRISMA-compliant meta-analysis. Medicine (Baltimore). 2021;100(30):e26751.
Hu N, Ji H. Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2022;43(9):5189–99.
Schumacher J, Peter RS, Nagel G, et al. Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol. 2020;27(8):1405–14.
Dorst J, Kuhnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613–7.
Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004–9.
Weisskopf MG, Levy J, Dickerson AS, Paganoni S, Leventer-Roberts M. Statin medications and amyotrophic lateral sclerosis incidence and mortality. Am J Epidemiol. 2022;191(7):1248–57.
Zeng P, Zhou X. Causal effects of blood lipids on amyotrophic lateral sclerosis: a Mendelian randomization study. Hum Mol Genet. 2019;28(4):688–97.
Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67(202):201 e201-202 e206.
Mignarri A, Malandrini A, Del Puppo M, et al. Treatment of SPG5 with cholesterol-lowering drugs. J Neurol. 2015;262(12):2783–5.
Loh WJ, Watts GF. The inherited hypercholesterolemias. Endocrinology and Metabolism Clinics of North America. 2022.
Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). J Inherit Metab Dis. 2017;40(6):771–81.
Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, et al. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. Eur J Neurol. 2011;18(10):1203–11.
Muntean DM, Thompson PD, Catapano AL, et al. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today. 2017;22(1):85–96.
Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010;10(1):16–21.
Manzar H, Abdulhussein D, Yap TE, Cordeiro MF. Cellular consequences of coenzyme Q10 deficiency in neurodegeneration of the retina and brain. Int J Mol Sci. 2020;21(23):9229.
Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363(9412):892–4.
Haseeb M. Thompson PD 2021 The effect of statins on RyR and RyR-associated disease. J Appl Physiol (1985). 1985;131(2):661–71.
Ward NC, Watts GF, Eckel RH. Statin Toxicity. Circ Res. 2019;124(2):328–50.
留言 (0)